Vi-Siblin (Ispaghula Husk): Uses, Dosage & Side Effects
Bulk-forming fiber laxative for constipation and irregular bowel habits
Quick Facts About Vi-Siblin
Key Takeaways About Vi-Siblin
- Always take with plenty of fluid: Each dose must be taken with at least one full glass of water or other liquid to prevent choking or esophageal obstruction
- Works for both constipation and loose stools: Ispaghula husk normalizes bowel function in both directions by absorbing water and adding bulk
- Start low, increase gradually: Begin with one dose per day and increase slowly over 3-7 days to minimize bloating and gas
- Safe during pregnancy and breastfeeding: Vi-Siblin is not absorbed systemically, making it a first-line option for constipation in pregnancy
- Separate from other medications: Take Vi-Siblin at least 30-60 minutes before or after other medicines to avoid reduced absorption
What Is Vi-Siblin and What Is It Used For?
Vi-Siblin is a bulk-forming fiber preparation containing ispaghula husk (psyllium husk), a natural plant fiber derived from the seed coat of Plantago ovata. It normalizes bowel function by absorbing water in the intestinal tract, increasing stool volume, and promoting healthy peristalsis. Vi-Siblin is used to treat constipation, loose stools, and irregular bowel habits in adults and children aged 2 years and over.
Ispaghula husk, the active ingredient in Vi-Siblin, is one of the most widely studied and recommended natural fiber supplements in the world. It belongs to the class of bulk-forming laxatives, which are considered the gentlest and most physiological approach to managing bowel irregularities. Unlike stimulant laxatives that directly irritate the intestinal wall, ispaghula husk works by a purely mechanical mechanism: it absorbs water to form a soft, gel-like mass that increases the volume and moisture content of stool.
This dual-action mechanism is what makes Vi-Siblin uniquely effective for both constipation and loose stools. In constipation, the increased bulk stimulates natural peristaltic contractions, helping to move stool through the colon more efficiently. In cases of loose stools or mild diarrhea, the gel-forming properties of ispaghula absorb excess water, resulting in firmer, more formed stools. This normalization of bowel function makes ispaghula husk a versatile and widely recommended treatment.
According to the World Gastroenterology Organisation (WGO) and the British National Formulary (BNF), bulk-forming laxatives such as ispaghula husk are recommended as first-line treatment for chronic constipation before considering osmotic or stimulant laxatives. The European Medicines Agency (EMA) has issued a well-established use monograph confirming the efficacy and safety of ispaghula husk for the treatment of habitual constipation and conditions requiring easier passage of softer stool.
Beyond its primary use for bowel regulation, research has shown that regular ispaghula husk intake may provide additional health benefits, including modest reductions in blood cholesterol levels and improvements in glycemic control in patients with type 2 diabetes. The U.S. Food and Drug Administration (FDA) has authorized a health claim linking soluble fiber from psyllium husk to a reduced risk of coronary heart disease when consumed as part of a diet low in saturated fat and cholesterol.
Vi-Siblin is not an immediate-acting laxative. It typically takes 1-3 days for the initial effect and 3-7 days for the full benefit. This is because the fiber needs time to absorb water and build up sufficient stool volume to stimulate normal bowel contractions. Patience and consistent use are key to achieving optimal results.
What Should You Know Before Taking Vi-Siblin?
Vi-Siblin is generally safe for most people, but it must not be used by individuals with swallowing difficulties, gastrointestinal obstructions, or bowel paralysis. Always take it with adequate fluid to prevent choking, and separate it from other medications by at least 30-60 minutes.
While Vi-Siblin is an over-the-counter product with an excellent safety profile, there are important considerations to be aware of before starting treatment. Understanding the contraindications, precautions, and potential drug interactions will help you use Vi-Siblin safely and effectively. As with any medication, reading the product information carefully and consulting your healthcare provider when uncertain is always recommended.
Contraindications
Do not use Vi-Siblin in the following situations:
- Allergy to ispaghula husk or any other ingredient in the product (sucrose, sodium chloride)
- Swallowing difficulties (dysphagia) of any kind, including conditions affecting the throat or esophagus
- Gastrointestinal narrowing (stenosis), particularly of the esophagus or upper stomach (cardia)
- Intestinal obstruction (ileus) or any condition causing a blockage in the gastrointestinal tract
- Bowel paralysis (paralytic ileus) or megacolon (abnormally enlarged colon)
Warnings and Precautions
Talk to your doctor or pharmacist before using Vi-Siblin if you have a history of swallowing difficulties or other problems affecting your throat or esophagus. This is particularly important because ispaghula husk rapidly swells on contact with water, and if it begins to swell before reaching the stomach, it could potentially cause obstruction in the esophagus.
Vi-Siblin must always be taken with an adequate amount of fluid — at least one full glass (approximately 200-250 ml) of water or another liquid per dose. Without sufficient fluid, the product may swell and block the throat or esophagus, creating a choking hazard. Never take Vi-Siblin dry or attempt to swallow the granules without mixing them into liquid or food.
Do not take Vi-Siblin immediately before going to bed or while lying down. Always take it in an upright position to ensure the product reaches the stomach safely. If you experience chest pain, difficulty swallowing, or difficulty breathing after taking Vi-Siblin, seek medical attention immediately.
Use in Children
Vi-Siblin can be used in children aged 2 years and older, but only under the supervision and prescription of a physician. The product is not recommended for children under 2 years of age due to insufficient data on safety and efficacy in this age group. Children should always be supervised when taking Vi-Siblin to ensure they consume adequate fluid with each dose.
Pregnancy and Breastfeeding
Vi-Siblin can be used during pregnancy and breastfeeding when dietary changes alone (such as increased fiber intake from fruits, vegetables, and whole grains) have not adequately relieved constipation. Ispaghula husk is not absorbed into the bloodstream and acts entirely within the gastrointestinal tract, making it one of the safest options available for managing pregnancy-related constipation.
Constipation affects up to 40% of pregnant women, primarily due to hormonal changes (elevated progesterone levels) that slow intestinal motility, iron supplementation, and the physical pressure of the growing uterus on the bowel. The American College of Obstetricians and Gynecologists (ACOG) and the National Institute for Health and Care Excellence (NICE) both recommend bulk-forming laxatives as a first-line pharmacological treatment for constipation in pregnancy when lifestyle measures are insufficient.
Driving and Operating Machinery
Vi-Siblin does not affect the ability to drive or operate machinery. It has no known central nervous system effects and does not cause drowsiness, dizziness, or impaired coordination.
Important Information About Excipients
Vi-Siblin contains sucrose (2.28 g per measuring spoon/sachet). If you take the maximum recommended dose of 3 measuring spoons per day, the total daily sucrose intake from Vi-Siblin is 6.84 g. This should be taken into account by patients with diabetes mellitus. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Vi-Siblin.
Vi-Siblin also contains sodium (33 mg per measuring spoon/sachet), which is equivalent to 1.65% of the WHO recommended maximum daily intake of 2 g sodium for adults. This should be considered by patients on a sodium-restricted diet.
How Does Vi-Siblin Interact with Other Drugs?
Vi-Siblin should be taken at least 30-60 minutes before or after other medications, as it may delay the absorption of concurrently administered drugs. Particular caution is needed with diabetes medications, thyroid hormones, anti-diarrheal agents, and drugs that reduce intestinal motility such as opioids.
Because ispaghula husk forms a viscous gel in the gastrointestinal tract, it can physically trap and delay the absorption of other medications taken at the same time. This does not reduce the total amount of drug absorbed but may delay the onset of its effect. For this reason, a general rule applies: always separate Vi-Siblin from other medications by at least 30 minutes to 1 hour.
Two categories of medications require special attention when used concurrently with Vi-Siblin. First, diabetes medications (including insulin, metformin, and sulfonylureas) may need dose adjustment because ispaghula husk can slow the absorption of carbohydrates, potentially affecting blood glucose levels and the timing of glucose-lowering drug action. Second, thyroid hormones (particularly levothyroxine) are highly sensitive to changes in absorption timing, and concurrent use with ispaghula husk may require dose adjustment and monitoring of thyroid function.
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| Diabetes medications (insulin, metformin, sulfonylureas) | Altered glucose absorption; may change drug timing | Moderate | Inform your doctor; dosage adjustment may be needed |
| Thyroid hormones (levothyroxine) | Delayed absorption of levothyroxine | Moderate | Separate by at least 4 hours; monitor thyroid levels |
| Anti-diarrheal agents (loperamide) | Increased risk of intestinal obstruction | Major | Do NOT use together |
| Opioid analgesics (codeine, morphine, tramadol) | Combined reduction of intestinal motility; risk of obstruction | Major | Do NOT use together without medical supervision |
| Lithium | Potential reduced lithium absorption | Moderate | Separate by at least 2 hours; monitor lithium levels |
| Carbamazepine | Potential reduced carbamazepine absorption | Moderate | Separate by at least 2 hours |
| Digoxin | Potential reduced digoxin absorption | Moderate | Separate by at least 2 hours; monitor digoxin levels |
As a precaution, take Vi-Siblin at least 30-60 minutes before or after any other medication. If you take multiple daily medications, consider taking Vi-Siblin at a time that allows adequate separation from your other drugs. Always inform your doctor or pharmacist about all medications you are taking, including over-the-counter products and supplements.
What Is the Correct Dosage of Vi-Siblin?
The standard adult dose of Vi-Siblin is 1 measuring spoon or sachet (approximately 6 g) taken 2-3 times daily, mixed with a full glass of liquid. Treatment should start with one dose per day and be gradually increased over 3-7 days. Children's dosing is weight- and age-dependent and requires medical supervision.
Vi-Siblin should always be used exactly as described in the product information or as directed by a healthcare professional. The key principle of dosing is to start low and increase gradually, which minimizes the temporary bloating and gas that commonly occurs when fiber intake is first increased. People with particularly sensitive digestive systems should extend the gradual increase period to 1-2 weeks.
| Age Group | Starting Dose | Maintenance Dose | Maximum Daily Dose | Special Notes |
|---|---|---|---|---|
| Adults (18+ years) | 1 measuring spoon (6 g) once daily | 1 measuring spoon 2-3 times daily | 3 measuring spoons (18 g) | Increase gradually over 3-7 days |
| Children over 6 years | 1 measuring spoon once daily | 1 measuring spoon 2 times daily | 2 measuring spoons (12 g) | Only under medical supervision |
| Children 2-6 years | ½ measuring spoon once daily | ½ measuring spoon 2 times daily | 1 measuring spoon (6 g) | Only on doctor's prescription |
| Children under 2 years | Not recommended | Not recommended | Not recommended | Insufficient safety/efficacy data |
How to Take Vi-Siblin
Vi-Siblin granules can be prepared in several ways, but the critical requirement is always the same: every dose must be accompanied by at least one full glass (200-250 ml) of liquid. Here are the recommended methods:
- Mixed into a beverage: Stir the granules into a glass of water, milk, juice, or another drink. The mixture will thicken slightly — drink it promptly before it becomes too thick
- Sprinkled on food: You can sprinkle the granules on or mix them into yogurt, porridge, cereal, or even savory dishes like pasta sauce. Even when mixed with food, always drink a full glass of liquid alongside it
- Using the measuring spoon: For the granule jar formulation, use the enclosed measuring spoon for accurate dosing. One level measuring spoon equals approximately 6 g
Do not take Vi-Siblin immediately before going to bed or while lying down. Always take it in an upright, seated or standing position. Never swallow the dry granules without liquid, as this creates a serious choking hazard.
Missed Dose
If you forget to take a dose of Vi-Siblin, simply take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose. Since Vi-Siblin works by building up fiber in the digestive system over time, missing a single dose will not significantly affect the overall treatment outcome.
Overdose
If you or someone else has taken significantly more Vi-Siblin than recommended, contact a healthcare provider or poison control center for assessment and advice. Overdose with ispaghula husk may cause abdominal discomfort, excessive gas, and potentially intestinal obstruction. The primary treatment for overdose symptoms is ensuring adequate fluid intake to prevent obstruction.
If a child has accidentally ingested a large amount of Vi-Siblin, seek medical attention promptly. Provide the child with plenty of water to drink and monitor for signs of abdominal distress.
What Are the Side Effects of Vi-Siblin?
The most common side effects of Vi-Siblin are abdominal cramps and increased gas, particularly during the first few days of treatment. These are typically mild and resolve as the body adjusts. Serious side effects such as allergic reactions or intestinal obstruction are rare and usually related to inadequate fluid intake.
Like all medicines, Vi-Siblin can cause side effects, although not everybody gets them. Bulk-forming fiber supplements commonly cause temporary gastrointestinal discomfort when first started, primarily because the gut microbiome needs time to adapt to the increased fiber load. These initial symptoms almost always resolve within the first 1-2 weeks of regular use, particularly when dosing is increased gradually as recommended.
The most important safety consideration is adequate fluid intake. The majority of serious adverse events associated with ispaghula husk products — including esophageal and intestinal obstruction — have occurred when the product was taken without sufficient liquid. Adhering to the fluid requirements effectively eliminates this risk for most users.
Common Side Effects
May affect up to 1 in 10 users
- Abdominal cramps or mild stomach pain
- Increased flatulence (gas)
- Bloating or abdominal distension
Rare Side Effects
May affect up to 1 in 1,000 users
- Allergic reactions (hay fever-like symptoms, skin rash, runny nose, conjunctivitis)
- Hypersensitivity reactions — particularly in people with occupational exposure to psyllium-containing products
Very Rare Side Effects
May affect up to 1 in 10,000 users
- Anaphylactic reactions (severe, life-threatening allergic reactions)
Frequency Not Known
Cannot be estimated from available data
- Hypersensitivity reactions
- Abdominal distension (bloating)
- Obstruction of the intestinal tract or esophagus (particularly with inadequate fluid intake)
If you experience bloating or increased gas when starting Vi-Siblin, this is a normal response that typically improves within 1-2 weeks. To minimize these effects: (1) Start with a low dose and increase gradually, (2) Ensure you drink plenty of water throughout the day, not just with your dose, and (3) Maintain regular physical activity, which helps reduce intestinal gas. If symptoms persist beyond 2-3 weeks, consult your healthcare provider.
Reporting Side Effects
If you experience any side effects, whether listed above or not, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority (for example, the Medicines and Healthcare products Regulatory Agency [MHRA] in the UK, the FDA in the US, or the European Medicines Agency [EMA]). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Vi-Siblin?
Store Vi-Siblin at room temperature, out of the sight and reach of children. Do not use after the expiration date printed on the packaging. Keep the container tightly closed to protect from moisture.
Proper storage of Vi-Siblin is straightforward but important to maintain the product's quality and efficacy. Ispaghula husk is hygroscopic, meaning it readily absorbs moisture from the environment. If the granules are exposed to excessive humidity, they may begin to clump or swell prematurely, reducing their effectiveness and making accurate dosing difficult.
- Storage temperature: Store at room temperature. No special temperature requirements
- Moisture protection: Keep the jar or sachets tightly closed after each use. Store in a dry place away from the bathroom
- Child safety: Keep this medicine out of the sight and reach of children
- Expiry date: Do not use Vi-Siblin after the expiration date stated on the packaging. The expiration date refers to the last day of that month
- Disposal: Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures help protect the environment
What Does Vi-Siblin Contain?
Vi-Siblin contains ispaghula husk as the active ingredient (610 mg per gram of granules in the standard formulation), with sucrose and sodium chloride as inactive ingredients. It is available in bulk jars (250 g and 500 g) and individual dose sachets (6 g each).
Active Ingredient
The active substance is ispaghula husk (also known internationally as psyllium husk). One gram of Vi-Siblin granules contains 610 mg of ispaghula husk in the standard formulation. The Vi-Siblin S formulation contains 880 mg of ispaghula husk per gram. Ispaghula husk is derived from the seed coating of Plantago ovata, a plant native to South Asia that has been used in traditional medicine for centuries.
Inactive Ingredients (Excipients)
- Sucrose: 2.28 g per measuring spoon/sachet — provides a mildly sweet taste to improve palatability
- Sodium chloride: 33 mg sodium per measuring spoon/sachet — equivalent to 1.65% of the WHO recommended maximum daily sodium intake for adults
Packaging Sizes
- Granule jars: 250 g and 500 g (with enclosed measuring spoon)
- Individual dose sachets: Boxes of 20, 50, or 100 sachets (6 g each)
Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Vi-Siblin
Vi-Siblin is a bulk-forming fiber supplement containing ispaghula husk (psyllium), used to normalize bowel function. It helps relieve both constipation and loose stools by absorbing water in the intestine to increase stool volume and promote regular bowel movements. It is available over the counter for adults and children from age 2 (under medical supervision for children). Beyond bowel regulation, ispaghula husk may also help lower cholesterol levels and improve blood sugar control when used regularly.
Vi-Siblin granules should always be mixed with a full glass of water, milk, juice, or another beverage before drinking. You can also sprinkle the granules on food such as yogurt or porridge, but you must still drink a full glass of liquid alongside it. Never take Vi-Siblin dry or without adequate fluid, as this can cause choking or esophageal obstruction. Always take it in an upright position and not immediately before bedtime or while lying down.
Yes, Vi-Siblin can be used during pregnancy and breastfeeding when dietary changes alone are insufficient to relieve constipation. Ispaghula husk is not absorbed into the bloodstream — it works entirely within the gastrointestinal tract — making it one of the safest laxative options during pregnancy. Both ACOG and NICE recommend bulk-forming laxatives as first-line pharmacological treatment for constipation in pregnancy. However, if you are unsure, always consult your healthcare provider.
Vi-Siblin typically begins to normalize bowel function within 1-3 days, but the full effect may take 3-7 days to develop. Treatment should start with one dose per day, gradually increasing until satisfactory bowel function is achieved. People with sensitive stomachs should increase the dose slowly over 1-2 weeks. Unlike stimulant laxatives, Vi-Siblin does not produce immediate bowel movements — it works gradually by building up fiber volume in the digestive system.
Common side effects (up to 1 in 10 users) include abdominal cramps and increased gas, particularly at the start of treatment. These symptoms are usually temporary and resolve within 1-2 weeks as the body adjusts. Rare side effects include allergic reactions such as skin rash or hay fever-like symptoms. Very rare anaphylactic reactions have been reported. The most important preventable risk is intestinal or esophageal obstruction, which can occur if the product is taken without sufficient fluid. Always follow the fluid intake recommendations.
Vi-Siblin can be used in children aged 2 years and older, but only under the supervision and prescription of a physician. Children aged 2-6 years typically take half a measuring spoon twice daily, while children over 6 years take one measuring spoon twice daily. Vi-Siblin is not recommended for children under 2 years due to insufficient safety and efficacy data. Always ensure children drink adequate fluid with each dose, and supervise younger children during administration.
References
- European Medicines Agency (EMA). Community herbal monograph on Plantago ovata Forssk., seminis tegumentum. HMPC/2013/19. 2013.
- World Gastroenterology Organisation (WGO). WGO Practice Guideline: Constipation — A Global Perspective. 2010 (updated 2023).
- National Institute for Health and Care Excellence (NICE). Constipation in adults: diagnosis and management. Clinical guideline [CG171]. 2023.
- British National Formulary (BNF). Ispaghula husk monograph. Updated 2025.
- McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. J Acad Nutr Diet. 2017;117(2):251-264.
- U.S. Food and Drug Administration (FDA). Health Claims: Soluble Fiber from Certain Foods and Risk of Coronary Heart Disease. 21 CFR 101.81. 1998.
- Ziai SA, et al. Psyllium decreased serum glucose and glycosylated hemoglobin significantly in diabetic outpatients. J Ethnopharmacol. 2005;102(2):202-207.
- American College of Obstetricians and Gynecologists (ACOG). Committee Opinion No. 757: Approaches to Limit Intervention During Labor and Birth. 2019.
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. 2023.
- Rao SSC, et al. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41(12):1256-1270.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed physicians specializing in gastroenterology, clinical pharmacology, and internal medicine. Our team follows international medical guidelines including those from the WHO, EMA, NICE, and BNF.
All medical claims are supported by peer-reviewed research and international clinical guidelines (Evidence Level 1A)
Content reviewed by iMedic Medical Review Board. No commercial funding or pharmaceutical sponsorship
Content is reviewed and updated regularly to reflect the latest medical evidence and guideline changes
We evaluate evidence quality using the internationally recognized GRADE framework for transparent assessment